
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Hematologic Oncology Update
00:00
Venetoclax plus anti‑CD20 outcomes
She compares venetoclax‑obinutuzumab outcomes, median PFS, and tradeoffs of fixed‑duration therapy versus continuous BTK.
Play episode from 04:49
Transcript


